ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
Rajdeep is an accomplished business leader with a strong techno-commercial background in the healthcare and diagnostic sector
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
The company also reported significant progress toward its internally defined Sustainable Development Goals
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
Angelini Ventures has already invested €125 million in 22 startups
Subscribe To Our Newsletter & Stay Updated
